Clinical Trial Update: Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating ACZ885 (canakinumab) for safety and vascular outcomes in patients with atherosclerosis and either type 2 diabetes or prediabetes comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Prediabetes
• Type 2 Diabetes Mellitus

Drugs mentioned

• ACZ885 (canakinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Diabetes Mellitus, Type 2, Atherosclerosis | Phase 2 | Status: COMPLETED | Results posted: 2015-03-06